RedShiftBio

About

RedShiftBio is a life sciences technology company based in Burlington, Massachusetts. The company specializes in analytical instrumentation for the research, development, manufacturing, and quality control of protein therapeutic drugs and biomolecules. RedShiftBio has developed proprietary Microfluidic Modulation Spectroscopy (MMS) technology, which allows for ultra-sensitive measurements of molecular structure, concentration, stability, and aggregation in various biomolecules. The company offers a range of fully automated instruments powered by MMS, including the Aurora and Aurora TX platforms for biophysical characterization, the Apollo system for precise protein measurements, and the AQS3 Pro for secondary structure analysis. Their HaLCon platform provides real-time protein titer measurement, enhancing manufacturing efficiency. RedShiftBio's instruments are utilized by leading global biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) for various applications in drug development and bioprocessing. Founded with expertise from major instrumentation firms, RedShiftBio has received significant funding and employs a dedicated team to support its mission of advancing analytical tools in life science research and biopharmaceutical development.